Today Companies Catalysts Feed Ask Sessions Audit

checking sources…P2 · Buy-side

Loading…

Pharmaverse shows analysis and evidence. It does not make recommendations — no buy, sell, hold, or price target, by design.

← Home

Indication added

WHAT HAPPENED

CTGOV◆ diff-detectedINDICATION_ADDED

Indication added

Change set — field-level diff

conditions

Non-hodgkin Lymphoma

→

Non-hodgkin Lymphoma,Recurrent Diffuse Large B-Cell Lymphoma,Recurrent Mantle Cell Lymphoma,Refractory Mantle Cell Lymphoma,Refractory Marginal Zone Lymphoma

Occurred 2026-10-02 23:35Z·Ingested 2026-10-02 23:35Z·confidence 1.00

WHY IT MATTERS

↑★★☆☆☆Materiality 26.41 / 100financial34.51strategic41.41regulatory22.01scientific29.51competitive39.51operational12.41reputational5.51Stars are a band. The number is the value.26/ 100for . Direction is stored per entity — there is no global good or bad.

[why this score?]

financial34.51strategic41.41regulatory22.01scientific29.51competitive39.51operational12.41reputational5.51

Seven dimensions, unsigned magnitude 0–100. Direction is resolved separately, per entity, because one event is good for one name and bad for another.

WHO ELSE

No other named entities identified.This event has no scored competitor read-through.

WHAT IT CHANGES

No real valuation-relevant phase transition on a resolved asset for this event.This section fires only when the event carries a resolved asset and a real phase change — not guessed for every event.

EVIDENCE

CTGOVNCT07763210confidence 1.00

Open the primary source ↗